Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Impact of lipid-lowering therapy on the prevalence of dyslipidaemia in patients at high-risk of cardiovascular events in UK primary care - a retrospective database study.

Jameson K, Amber V, D'Oca K, Mills D, Giles A, Ambegaonkar B.

Int J Clin Pract. 2013 Dec;67(12):1228-37. doi: 10.1111/ijcp.12238.

2.

Attainment of normal lipid levels among high cardiovascular risk patients: pooled analysis of observational studies from the United Kingdom, Sweden, Spain and Canada.

Ambegaonkar BM, Bash LD, Chirovsky DR, Jameson K, Grant S, Nocea G, Pettersson B, Sazonov V.

Eur J Intern Med. 2013 Oct;24(7):656-63. doi: 10.1016/j.ejim.2013.07.005.

PMID:
23953848
3.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
4.

Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS).

Devroey D, Radermecker RP, Van der Schueren BJ, Torbeyns B, Jaken RJ.

Int J Clin Pract. 2014 Feb;68(2):180-7. doi: 10.1111/ijcp.12315.

5.

Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.

Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.

Clin Ther. 2007 Aug;29(8):1671-81.

PMID:
17919548
6.

Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS).

Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, Li Z, Wei Y, Ambegaonakr BM, Hu D; DYSIS-China Study Investigators..

Atherosclerosis. 2014 Aug;235(2):463-9. doi: 10.1016/j.atherosclerosis.2014.05.916.

PMID:
24950001
7.

Mixed dyslipidemias in primary care patients in France.

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E.

Vasc Health Risk Manag. 2012;8:247-54. doi: 10.2147/VHRM.S27668.

8.

Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs.

Laforest L, Souchet T, Moulin P, Ritleng C, Desamericq G, Le Jeunne P, Schwalm MS, Van Ganse E.

Arch Cardiovasc Dis. 2009 Jan;102(1):43-50. doi: 10.1016/j.acvd.2008.06.021.

9.

Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.

Gitt AK, Jünger C, Smolka W, Bestehorn K.

Clin Res Cardiol. 2010 Nov;99(11):723-33. doi: 10.1007/s00392-010-0177-z.

10.

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.

Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators..

Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545.

PMID:
21450578
11.

Association between dyslipidemia and vascular events in patients treated with statins: report from the UK General Practice Research Database.

Sazonov V, Beetsch J, Phatak H, Wentworth C, Evans M.

Atherosclerosis. 2010 Jan;208(1):210-6. doi: 10.1016/j.atherosclerosis.2009.07.021.

PMID:
19766999
13.

Prevalence of lipid abnormalities and attainment of normal lipid levels among patients with dyslipidaemia: a pooled analysis of observational studies from five Asian countries.

Unniachan S, Bash LD, Khovidhunkit W, Sri RZ, Vicaldo E, Recto C 2nd, Ambegaonkar BM.

Int J Clin Pract. 2014 Aug;68(8):1010-9. doi: 10.1111/ijcp.12407.

PMID:
24666791
14.

Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data.

Belsey J, de Lusignan S, Chan T, van Vlymen J, Hague N.

Curr Med Res Opin. 2008 Sep;24(9):2551-60. doi: 10.1185/03007990802321964 .

PMID:
18674409
15.

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS).

Raal FJ, Blom DJ, Naidoo S, Bramlage P, Brudi P.

Cardiovasc J Afr. 2013 Sep;24(8):330-8. doi: 10.5830/CVJA-2013-071.

16.

Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS).

Horgan S, Crowley J, Feely J, McAdam B, Shanahan E, Vaughan C.

Ir J Med Sci. 2011 Jun;180(2):343-9. doi: 10.1007/s11845-011-0702-8.

PMID:
21400212
17.

Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy.

Ray K, Wainwright NW, Visser L, Witteman J, Breteler M, Ambegaonkar B, Hofman A, Stricker B, Wareham N, Khaw KT, Sandhu M.

Heart. 2012 May;98(10):780-5. doi: 10.1136/heartjnl-2011-301405.

18.

Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe.

Halcox JP, Tubach F, Lopez-Garcia E, De Backer G, Borghi C, Dallongeville J, Guallar E, Medina J, Perk J, Sazova O, Sweet S, Roy C, Banegas JR, Rodriguez-Artalejo F.

PLoS One. 2015 Feb 18;10(2):e0115270. doi: 10.1371/journal.pone.0115270.

20.

Prevalence and control of dyslipidaemia among diabetic patients with microalbuminuria in a Chinese hospital.

Wang SH, Wang L, Zhou Y, Guo YJ, Yuan Y, Li FF, Huang Y, Xia WQ.

Diab Vasc Dis Res. 2013 Mar;10(2):169-78. doi: 10.1177/1479164112454756.

PMID:
22906862

Supplemental Content

Support Center